Compounding Pharmacy Guide: What Patients Actually Need to Know

You've probably heard about compounding pharmacies in the context of GLP-1 medications, and you probably have a lot of unanswered questions. Are compounded versions of semaglutide still legal? Is the quality any good? What's actually going on with the FDA?

Most of what's being written on this topic right now skips the details that actually matter to patients. This guide covers the regulatory framework, the quality differences that separate safe pharmacies from risky ones, and the current legal situation for compounded GLP-1 medications. Clearly, without the spin.

To be clear about what this guide is and isn't: this is an explanation of how compounding pharmacies work, what the regulations mean, and how to evaluate quality. It's not a directory of where to get compounded Ozempic. That framing would be irresponsible given how fast the legal situation is moving.

What Is a Compounding Pharmacy?

A compounding pharmacy is a licensed pharmacy that creates customized medications for individual patients. Instead of dispensing a pre-manufactured pill or vial made in a commercial facility, a compounding pharmacist combines, mixes, or alters ingredients to create a medication that isn't available commercially, or isn't available in the form a specific patient needs.

That definition sounds simple, but compounding pharmacies exist on a spectrum that spans everything from a small neighborhood pharmacy making a liquid version of a pill for a child who can't swallow tablets, to large-scale facilities producing thousands of vials of injectable medications per week. The regulatory framework treats those two situations very differently, and the differences matter to any patient considering a compounded medication.

Doctor Mike Hansen, a board-certified physician in Internal Medicine and Obesity Medicine, has explained the core issue clearly: the biggest driver of patient interest in compounding pharmacies is cost. Brand-name GLP-1 medications like Wegovy run around $1,300 per month, and Mounjaro (tirzepatide) around $1,600, with most insurance plans covering neither (Hansen, 2023). Compounded versions have typically cost $200-$400 per month. That gap is why so many patients started looking for alternatives.

How 503A and 503B Pharmacies Differ

The Drug Quality and Security Act (DQSA) of 2013 is the federal law that created the current compounding pharmacy regulatory structure. It established two distinct regulatory tracks (Section 503A and Section 503B), and understanding which one applies to a pharmacy is the most important piece of regulatory knowledge any patient can have (Congress, 2013).

503A pharmacies are traditional compounding pharmacies. They prepare medications based on individual patient prescriptions. A physician writes a script for a specific named patient, and the 503A pharmacy fills that prescription. These pharmacies are primarily regulated by state boards of pharmacy rather than the FDA. They do not have to follow the FDA's Current Good Manufacturing Practice (cGMP) standards, which are the stringent manufacturing requirements that commercial drug makers must meet. Their quality standards are set by USP Chapters 795 (non-sterile compounding) and 797 (sterile compounding) (Allen, 2013).

503B outsourcing facilities operate at a larger scale. They can produce medications without patient-specific prescriptions, selling directly to healthcare providers. They are registered with the FDA and must comply with cGMP standards, the same manufacturing quality requirements that pharmaceutical companies follow. This includes validated sterilization processes, potency testing, environmental monitoring, and detailed batch records (Bowman, 2015).

The practical difference for a patient is this: a 503B-registered facility has been inspected by the FDA, follows pharmaceutical-grade manufacturing standards, and can legally produce batches of medication without a named patient attached. A 503A pharmacy may be excellent. Its quality controls depend heavily on the individual pharmacy, its pharmacists, and state oversight rather than federal inspection.

Quality Standards: What USP 795 and 797 Actually Mean

When you hear that a compounding pharmacy "follows USP 795 and 797," here's what that means in practice.

USP Chapter 795 covers non-sterile compounding. It governs things like oral medications, topical creams, and capsules. The standards cover personnel training, equipment calibration, ingredient sourcing, stability testing, and documentation.

USP Chapter 797 is more stringent. It applies to sterile preparations: anything that goes into your body by injection or into your eyes. The injectable GLP-1 medications that have been compounded in large volumes are governed by 797 when prepared by a 503A pharmacy. The standards include ISO-classified cleanroom requirements, personnel gowning and training, sterility testing, and beyond-use dating rules (Thompson, 2023).

Beyond-use dates (BUDs) are the compounding equivalent of an expiration date, but they work differently. Commercial drugs are tested extensively for shelf life and get FDA-approved expiration dates based on that data. Compounded medications get BUDs based on USP category assignments, which are typically more conservative but may not account for every formulation variable. A community Reddit post from r/Retatrutide reported that pharmacy testing showed compounded tirzepatide and semaglutide retained potency for 150 days at room temperature and 300 days refrigerated. That's self-reported pharmacy data, not independent validation (Reddit, 2025).

The FDA's real concern with many compounding pharmacies has been the gap between what USP 797 requires and what actually happens in practice. The contamination incidents that led to regulatory enforcement have driven FDA to take a harder look at sterile compounding practices. These include a 2009 case published in Emerging Infectious Diseases documenting bloodstream infections from contaminated compounded fentanyl (Maragakis et al., 2009), and a 2006 outbreak of Serratia marcescens meningitis and deaths traced to improperly compounded betamethasone (Civen et al., 2006).

The Salt Form Controversy: Why This Matters for GLP-1 Compounding

This is the technical issue that has generated the most FDA enforcement activity against compounding pharmacies making semaglutide, and it's genuinely complicated.

Semaglutide (the active ingredient in Ozempic and Wegovy) exists in two chemical forms. The brand-name products use semaglutide base, the form that was studied in clinical trials like the STEP trials. Many compounding pharmacies were using semaglutide sodium, a salt form of the molecule.

The FDA took the position that semaglutide sodium is not the same drug as semaglutide base. They are different chemical entities with potentially different pharmacokinetic profiles. Because the brand-name drug uses the base form, and because there are no clinical studies establishing that the sodium salt behaves equivalently, FDA issued warning letters to pharmacies using the salt form, stating that those drugs would be considered adulterated and potentially misbranded (FDA Warning Letters, 2025-2026).

This isn't just regulatory paperwork. If a compounded medication uses a different salt form than the one studied in clinical trials, you cannot assume it works the same way or is equally safe. The FDA's 18 adverse event reports in their FAERS database related to compounded GLP-1 preparations flagged concerns including drug ineffectiveness, meaning some patients may have received preparations that didn't deliver the expected dose in the expected way.

The practical question for patients: if you received or considered compounded semaglutide, it's worth asking your prescribing physician specifically whether the pharmacy used semaglutide base or a salt form.

The Post-Shortage GLP-1 Legal Situation

This requires a careful timeline.

During 2022-2024, the FDA placed semaglutide (Ozempic and Wegovy) on its drug shortage list. When a drug is on the shortage list, compounding pharmacies can legally compound it under Section 503A and 503B, even though it is a commercially available drug (which would normally prohibit compounding). The logic is that if patients can't get the commercial version, a compounded version addresses an unmet medical need.

In February 2025, the FDA officially declared the semaglutide shortage resolved for all strengths (Doucette et al., 2025). The tirzepatide shortage had ended in late 2024. Once the shortage is resolved, the legal basis for compounding those specific drugs evaporates, at least for most compounding scenarios. A drug that is commercially available and not in shortage cannot generally be compounded for reasons of cost or preference alone.

The practical fallout has been messy. Compounding pharmacies that had built entire business models around GLP-1 compounding challenged the FDA's shortage determination in court. Multiple lawsuits sought to continue compounding beyond the shortage period. The FDA provided enforcement grace periods (windows during which the agency said it would not immediately pursue enforcement actions while the legal and logistical transitions sorted themselves out).

As of early 2026, FDA warning letters have continued to go out to compounding pharmacies that continue to produce GLP-1 medications without meeting the legal exceptions. The FDA's list of warning letters shows letters to facilities including Apothecary Pharma LLC (December 2025), GenoGenix LLC (January 2026), and MedisourceRx (December 2025), all cited for compounding adulterated drug products (FDA, 2025-2026).

Peter Attia MD, a physician specializing in longevity medicine, noted in October 2024 that the GLP-1 space changes more than almost any other topic he covers, reflecting how rapidly the regulatory and clinical picture has evolved even within a single year (Attia, 2024). That pace hasn't slowed.

What this means for patients: If you are currently using or considering compounded semaglutide or tirzepatide, confirm directly with the prescribing provider whether the pharmacy is legally authorized to compound the specific medication under current FDA guidance. FDA enforcement is active.

How to Evaluate a Compounding Pharmacy

Not all compounding pharmacies are equal, and the differences in quality can be significant. Here's what to actually look at.

PCAB Accreditation. The Pharmacy Compounding Accreditation Board (PCAB) is an accreditation program managed by URAC. A PCAB-accredited pharmacy has been independently assessed against compounding quality standards beyond what state licensure requires. It's not a guarantee of perfection, but it's a meaningful signal (Pirnay et al., 2018).

503B vs 503A registration. For sterile injectable medications specifically, a 503B-registered outsourcing facility is inspected by the FDA and held to cGMP standards. If a provider is recommending an injectable compounded medication, confirm whether the source pharmacy is 503B-registered. The FDA maintains a public list of registered 503B facilities.

State pharmacy license verification. Every compounding pharmacy should have an active license in the state where it operates. Most state pharmacy boards have online license lookup tools. Verifying the license takes two minutes and eliminates one category of risk.

Sterility and potency testing. Reputable compounding pharmacies test their preparations. For sterile injectables, this includes sterility testing of finished products and potency testing to confirm the labeled dose is actually in the vial. Ask whether the pharmacy conducts these tests and whether certificates of analysis are available for specific lot numbers.

Red flags to watch for:

• No physical address, or an address that doesn't match state licensing records
• Sells directly to patients without requiring a valid prescription
• No mention of pharmacist credentials or state licensure
• Pricing that seems too far below market rates (may reflect lower-quality active pharmaceutical ingredients)
• No answer when you ask about sterility testing or certificates of analysis

A 2018 paper in the Orphanet Journal of Rare Diseases noted that compounded medications require validated standard operating procedures and certificate of analysis for all ingredients, with full traceability records (Dooms et al., 2018). That's what a well-run compounding pharmacy provides. The fact that you have to ask for it tells you something.

Cost, Coverage, and What Access Actually Looks Like

For most patients, cost is the central issue. Here's what the numbers actually look like.

Brand-name GLP-1 medications without insurance:

• Ozempic (semaglutide 0.5-2mg): approximately $900-$1,000/month
• Wegovy (semaglutide 2.4mg): approximately $1,300/month
• Mounjaro/Zepbound (tirzepatide): approximately $1,200-$1,600/month

Compounded semaglutide (when legally available): approximately $150-$400/month depending on dose and pharmacy

Coverage reality: Most commercial insurance plans do not cover GLP-1 medications when prescribed for weight loss (as opposed to type 2 diabetes management). Medicare Part D explicitly excludes coverage for weight loss drugs, though this may change through pending legislation. Compounded medications are typically not covered by insurance regardless of indication.

Manufacturer savings programs: Novo Nordisk (Ozempic/Wegovy) and Eli Lilly (Mounjaro/Zepbound) both offer patient savings programs that can significantly reduce out-of-pocket costs for commercially insured patients. These programs have income and insurance requirements. For uninsured patients, the programs generally do not apply, but Novo Nordisk's Patient Assistance Program offers free medication for qualifying low-income patients.

The cost math is why so many patients have been drawn to compounded versions. The challenge is that cost savings don't mean much if the product isn't what it says it is. Evaluating quality is part of the calculation.

At HEXIS Health, we prescribe FDA-approved medications when they're appropriate and accessible for a patient's situation. When we do work with compounding pharmacies, we use facilities that meet the quality standards described above. Your physician will discuss what options make sense given your clinical picture, insurance, and the current regulatory environment. Not what's cheapest, and not what's in shortage at the moment.

Schedule a consultation to talk through GLP-1 options and what's currently available through our clinic.

Compounding and Related Medications: Where the Pieces Connect

Understanding compounding pharmacies requires understanding the medications they've been compounding most frequently. For GLP-1 medications specifically:

• The ozempic dosing schedule is relevant because the titration protocol matters. Compounded versions often involve self-administered injections where dose accuracy depends heavily on the pharmacy's preparation quality.
• The Wegovy dosage guide covers the full escalation protocol for semaglutide at weight-loss doses, which helps contextualize why patients seek compounded alternatives.
• Retatrutide, a newer triple agonist still in clinical trials, has also appeared in compounding pharmacy discussions as interest in next-generation GLP-1 compounds grows.
• For patients where GLP-1s aren't the right fit, metformin for weight loss is a well-established, FDA-approved option with a completely different access and cost profile.